Mr. Andre Rancourt of Tetra Bio Pharma reports

TETRA BIO-PHARMA AND INTELGENX ANNOUNCE THE SIGNING OF A DEFINITIVE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF A DRONABINOL XL TABLET

Tetra Bio Pharma Inc. and IntelGenx Corp. have signed a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol for the management of anorexia and cancer chemotherapy-related pain. The U.S. cancer pain market is expected to reach $5-billion in 2018. This definitive agreement follows the binding term sheet between the two companies that was announced on Feb. 9, 2017.

Pursuant to the definitive agreement, Tetra has exclusive rights to sell the product in North America, with a right of first negotiation for territories outside of the United States and Canada. Tetra will make an upfront payment to IntelGenx, in addition to set future milestone and royalty payments, based on the completion of an efficacy study, approvals from the U.S. Food and Drug Association and Health Canada, and the commercial launch of the product. IntelGenx will be responsible for the research and development of the product, including clinical studies, and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa controlled-release technology. Tetra will be responsible for financing the product development, and will own and control all regulatory approvals, including the related applications, and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the product.

"We are pleased to announce the closing of the definitive agreement with IntelGenx and look forward to working very hard with them to bring this much-needed product to patients suffering from cancer pain," said Andre Rancourt, chief executive officer of Tetra Bio Pharma. "The execution of this agreement is just the beginning for Tetra as we look forward to aggressively concluding future agreements as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs."

"The U.S. cancer pain market is expected to reach $5-billion in 2018, and the quick-growing medical cannabis industry is poised to capture a signature portion of that opportunity," said Dr. Horst G. Zerbe, president and CEO of IntelGenx. "We are pleased to be working with Tetra to bring this much-needed cannabinoid product to North American patients suffering from anorexia and cancer chemotherapy-related pain."

Background information

There are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy-related pain. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of tetrahydrocannabinol (THC) and its metabolite increases the abuse potential of cannabinoids like Dronabinol. The significant advantage of an oral mucoadhesive tablet based on IntelGenx's proprietary AdVersa controlled-release technology is that it can be adjusted to achieve a predetermined drug release pattern by increasing the residence time, promoting intimate contact with the mucosal tissue and increasing the bioadhesive properties of the dosage form. It is believed that, by deploying this technology in the controlled-release of THC, a longer time release of the drug will be achieved and, thereby, a rapid increase in the blood will be avoided. There will also potentially be improved bioavailability and reduced gastrointestinal side effects, making a sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain.

About IntelGenx Technologies Corp.

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property, and regulatory services. IntelGenx's state-of-the art manufacturing facility, established for the VersaFilm technology platform, supports lab-scale to pilot- and commercial-scale production, offering full-service capabilities to the company's clients.

About Tetra Bio Pharma Inc.

Tetra Bio Pharma is a multisubsidiary publicly traded company engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies.

We seek Safe Harbor.